COVID-19 infection in chronic myeloid leukemia patients
DOI:
https://doi.org/10.3126/jpahs.v8i3.28841Keywords:
Chronic Myeloid Leukemia, RT-PCR, SARS CoV-2, Tyrosine Kinase InhibitorAbstract
Introduction: Corona virus disease 2019(COVID-19) is an infectious disease caused by newly discovered coronavirus SARS CoV-2 (Severe acute respiratory syndrome coronavirus 2). Majority of the COVID-19 infections have mild symptoms in general populations but symptoms may be more severe in immunocompromised and elderly patients and may be in CML populations also. We expected most of CML patients in elderly age group may develop severe symptoms of COVID-19 and its severity may vary in different phases of the CML and different types of TKI being used.
Method: From January 2020 to June 2021 all adult CML patients receiving treatment from Patan Hospital, identified with SARS Cov-2 infection were included in the study. Those patients who had final outcome from COVID-19 infection was taken.
Result: The prevalence of SARS CoV-2 infection in CML population in our hospital is 2.60%. The COVID-19 infection was seen more on female population and younger age group less then 60 years old. Even though the infection rate was higher in the younger age group and infection rate was lesser in CML-CP group, mortality was higher in elderly and advances age group which was statically significant. Regardless of their symptoms, stages, severity of the symptoms, different TKI being used about 92% have fully recovered from COVID-19 infection.
Conclusion: About 92% of CML patients had fully recovered from COVID-19 infection. In our study advanced stage and elderly age group were associated with more severity of the disease and higher mortality rate.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
© Journal of Patan Academy of Health Sciences
Submission of the manuscript means that the authors agree to assign exclusive copyright to JPAHS. All authors must sign a Copyright Transfer and Author Agreement form upon submission of the manuscript to the Journal. The work shall not be published elsewhere in any language without the written consent of JPAHS. The articles published in this journal are protected by copyright which covers translation rights and the exclusive rights to reproduce and distribute all of the articles printed in the journal.